celecoxib has been researched along with risperidone in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (44.44) | 29.6817 |
| 2010's | 9 (50.00) | 24.3611 |
| 2020's | 1 (5.56) | 2.80 |
| Authors | Studies |
|---|---|
| Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Dalvie, D; Loi, CM; Smith, DA | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Brandstätter, B; Engel, RR; Krampe, K; Möller, HJ; Müller, N; Riedel, M; Scheppach, C; Schwarz, MJ; Sokullu, S; Ulmschneider, M | 1 |
| Ackenheil, M; Gruber, R; Möller, HJ; Müller, N; Riedel, M; Scheppach, C; Schwarz, MJ; Ulmschneider, M | 1 |
| Engel, RR; Müller, N; Riedel, M; Schwarz, MJ | 1 |
| Ahmadpour, O; Bresee, CJ; Delrahim, K; Dolnak, D; Maddux, RE; Rapaport, MH | 1 |
| Abbasi, SH; Ahmadi Abhari, SA; Akhondzadeh, S; Amini, H; Behnam, B; Tabatabaee, M | 1 |
| Goldstein, BI; Kemp, DE; McIntyre, RS; Soczynska, JK | 1 |
| Akhondzadeh, S; Asadabadi, M; Ashrafi, M; Forghani, S; Ghanizadeh, A; Hassanzadeh, E; Modabbernia, A; Mohammadi, MR | 1 |
| Brodney, MA; Obach, RS; Walker, GS | 1 |
| El-Sayed El-Sayad, M; El-Sayed El-Sisi, A; Osman, EY; Sayed Ramadan, E; Sokkar, SS | 1 |
| Akhondzadeh, S; Gholamian, F; Karkhaneh-Yousefi, MA; Khezri, R; Mohammadi, MR; Mohammadinejad, P; Mousavi, SY; Zeinoddini, A | 1 |
| Li, W; Lv, L; Shao, M; Shi, H; Song, M; Su, X; Yang, G; Yang, Y; Zhang, Y | 1 |
2 review(s) available for celecoxib and risperidone
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature.
Topics: Anti-Inflammatory Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Brief Psychiatric Rating Scale; Celecoxib; Clozapine; Comorbidity; Cytokines; Humans; Inflammation; Lithium Carbonate; Pyrazoles; Risperidone; Sulfonamides; Surveys and Questionnaires; Treatment Outcome | 2009 |
8 trial(s) available for celecoxib and risperidone
| Article | Year |
|---|---|
Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antipsychotic Agents; Celecoxib; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Pyrazoles; Risperidone; Schizophrenia; Severity of Illness Index; Sulfonamides; Treatment Outcome | 2002 |
COX-2 inhibition as a treatment approach in schizophrenia: immunological considerations and clinical effects of celecoxib add-on therapy.
Topics: Analysis of Variance; Antigens, CD; Antipsychotic Agents; Celecoxib; Cyclooxygenase Inhibitors; Cytokines; Double-Blind Method; Drug Therapy, Combination; Female; Flow Cytometry; Humans; Male; Psychiatric Status Rating Scales; Pyrazoles; Receptors, Interleukin-2; Receptors, Tumor Necrosis Factor; Receptors, Tumor Necrosis Factor, Type I; Risperidone; Schizophrenia; Sulfonamides; T-Lymphocytes; Time Factors; Treatment Outcome | 2004 |
Clinical effects of COX-2 inhibitors on cognition in schizophrenia.
Topics: Adult; Antipsychotic Agents; Celecoxib; Cognition; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Double-Blind Method; Female; Humans; Male; Psychiatric Status Rating Scales; Pyrazoles; Risperidone; Schizophrenia; Schizophrenic Psychology; Sulfonamides | 2005 |
The effects of celecoxib augmentation on cytokine levels in schizophrenia.
Topics: Adult; Benzodiazepines; Celecoxib; Cytokines; Double-Blind Method; Drug Synergism; Female; Humans; Male; Middle Aged; Olanzapine; Prospective Studies; Pyrazoles; Risperidone; Schizophrenia; Sulfonamides | 2006 |
Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antipsychotic Agents; Basal Ganglia Diseases; Celecoxib; Chronic Disease; Cyclooxygenase Inhibitors; Cytokines; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Iran; Male; Psychiatric Status Rating Scales; Pyrazoles; Risperidone; Schizophrenia; Sulfonamides; Th1 Cells | 2007 |
Celecoxib as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial.
Topics: Antipsychotic Agents; Autistic Disorder; Celecoxib; Child; Child, Preschool; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Psychiatric Status Rating Scales; Pyrazoles; Risperidone; Sulfonamides; Treatment Outcome | 2013 |
A Randomized, Double-Blind Placebo-Controlled Trial on Effectiveness and Safety of Celecoxib Adjunctive Therapy in Adolescents with Acute Bipolar Mania.
Topics: Adolescent; Antimanic Agents; Bipolar Disorder; Celecoxib; Child; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Lithium; Male; Risperidone; Treatment Outcome | 2017 |
Associations between expression of indoleamine 2, 3-dioxygenase enzyme and inflammatory cytokines in patients with first-episode drug-naive Schizophrenia.
Topics: Celecoxib; Cytokines; Female; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Male; Risperidone; Schizophrenia | 2021 |
8 other study(ies) available for celecoxib and risperidone
| Article | Year |
|---|---|
Identifying off-target effects and hidden phenotypes of drugs in human cells.
Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship | 2006 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Which metabolites circulate?
Topics: Humans; Metabolic Clearance Rate; Pharmaceutical Preparations | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Biosynthesis of Fluorinated Analogs of Drugs Using Human Cytochrome P450 Enzymes Followed by Deoxyfluorination and Quantitative Nuclear Magnetic Resonance Spectroscopy to Improve Metabolic Stability.
Topics: Aldehydes; Celecoxib; Cytochrome P-450 Enzyme System; Diethylamines; Fluorine; Halogenation; Humans; Hydroxylation; Indenes; Magnetic Resonance Spectroscopy; Microsomes, Liver; Midazolam; Pharmaceutical Preparations; Risperidone | 2016 |
Celecoxib and omega-3 fatty acids alone and in combination with risperidone affect the behavior and brain biochemistry in amphetamine-induced model of schizophrenia.
Topics: Amphetamine; Animals; Behavior, Animal; Brain; Celecoxib; Disease Models, Animal; Drug Therapy, Combination; Fatty Acids, Omega-3; Male; Malondialdehyde; Maze Learning; Rats; Risperidone; Schizophrenia; Tumor Necrosis Factor-alpha | 2016 |